Biogen Management
Management criteria checks 4/4
Biogen's CEO is Chris Viehbacher, appointed in Nov 2022, has a tenure of 1.75 years. total yearly compensation is $4.07M, comprised of 39.3% salary and 60.7% bonuses, including company stock and options. directly owns 0.005% of the company’s shares, worth CHF1.23M. The average tenure of the management team and the board of directors is 4.3 years and 5.2 years respectively.
Key information
Chris Viehbacher
Chief executive officer
US$4.1m
Total compensation
CEO salary percentage | 39.3% |
CEO tenure | 1.8yrs |
CEO ownership | 0.005% |
Management average tenure | 4.3yrs |
Board average tenure | 5.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | US$1b |
Mar 31 2024 | n/a | n/a | US$1b |
Dec 31 2023 | US$4m | US$2m | US$1b |
Sep 30 2023 | n/a | n/a | US$1b |
Jun 30 2023 | n/a | n/a | US$3b |
Mar 31 2023 | n/a | n/a | US$3b |
Dec 31 2022 | US$30m | US$154k | US$3b |
Compensation vs Market: Chris's total compensation ($USD4.07M) is about average for companies of similar size in the Swiss market ($USD4.95M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Viehbacher (63 yo)
1.8yrs
Tenure
US$4,069,913
Compensation
Mr. Christopher A. Viehbacher, also known as Chris, is Director of Innocoll Holdings plc from July 24, 2017. He joined the Innocoll Holdings plc on July 24, 2017. He serves as President, Chief Executive Of...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 1.8yrs | US$4.07m | 0.0048% $ 1.2m | |
Executive VP & CFO | 4yrs | US$7.17m | 0.013% $ 3.4m | |
Head of Pharmaceutical Operations & Technology | 2.6yrs | US$5.71m | 0.0066% $ 1.7m | |
Executive VP & Chief Legal Officer | 18.6yrs | US$6.70m | 0.035% $ 9.1m | |
Head of Global Product Strategy & Commercialization | 3.6yrs | US$5.45m | 0.0067% $ 1.7m | |
Senior VP & Chief Accounting Officer | 5.8yrs | no data | 0.0043% $ 1.1m | |
Senior VP & Head of Investor Relations | 1.4yrs | no data | no data | |
Chief Communication Officer & Head of Corporate Affairs | 4.6yrs | no data | no data | |
Executive VP & Head of Corporate Development | 1.3yrs | no data | 0.00045% $ 115.1k | |
Executive VP & Chief Human Resources Officer | 7.1yrs | US$5.08m | 0.0093% $ 2.4m | |
President & Head of North America | 7.1yrs | no data | no data | |
Head of Biotherapeutics & Medicinal Sciences | 7.1yrs | no data | no data |
4.3yrs
Average Tenure
58yo
Average Age
Experienced Management: BIIB's management team is considered experienced (4.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
President | 1.8yrs | US$4.07m | 0.0048% $ 1.2m | |
Independent Director | 14.4yrs | US$435.32k | 0.013% $ 3.3m | |
Independent Director | 5.2yrs | US$425.73k | 0.0045% $ 1.1m | |
Independent Chair of the Board | 14.6yrs | US$646.13k | 0.017% $ 4.4m | |
Independent Director | 14.4yrs | US$418.02k | 0.014% $ 3.6m | |
Independent Director | 3.2yrs | US$412.90k | 0.0031% $ 779.8k | |
Independent Director | less than a year | no data | 0.00092% $ 235.2k | |
Independent Director | 5.2yrs | US$433.23k | 0.0051% $ 1.3m | |
Independent Director | 1.2yrs | US$334.53k | 0.0019% $ 483.2k |
5.2yrs
Average Tenure
65yo
Average Age
Experienced Board: BIIB's board of directors are considered experienced (5.2 years average tenure).